You are here
GLSynthesis Inc.
UEI: N/A
# of Employees: 14
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Development of a fluorescence ABCG liposomal multidrug transporter assay
Amount: $1,149,278.00DESCRIPTION provided by applicant In Phase I as proposed we successfully demonstrated proof of principle for the Flurosome trans abcg assay This innovative assay characterizes how compounds int ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
Production and inhibition assay for bile salt export protein
Amount: $243,266.00DESCRIPTION provided by applicant The objective of the proposed project is to design and construct a highly specific and high throughput in vitro biological assay system to characterize the interac ...
SBIRPhase I2015Department of Health and Human Services National Institutes of Health -
A novel drug detection assay using fluorescent biosensor technology
Amount: $320,466.00DESCRIPTION provided by applicant This phase project has as its overall objectives to design engineer optimize and implement a novel genetically encoded fluorescent drug sensor FDS based o ...
STTRPhase I2015Department of Health and Human Services National Institutes of Health -
Development of a fluorescence liposomal ABCG2 Multidrug Transporter assay
Amount: $363,564.00ABSTRACT In this project we propose to exploit the recent successful isolation and reconstitution of the important ATP- dependent drug efflux transporter, ABCG2 (BCRP, Breast Cancer Resistance Protei ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
Healing of Diabetic Ulcers with Gaseous Nitric Oxide Generated from Room Air
Amount: $237,357.00DESCRIPTION: Androgen action is the net result of opposing pathways of steroid biosynthesis and metabolism. It is now widely recognized that testosterone (T) is an androgenic precursor of the more po ...
SBIRPhase I2013Department of Health and Human Services National Institutes of Health -
Novel Antithrombotic Diadenosine Tetraphosphate Analogs
Amount: $3,396,941.00DESCRIPTION: Undesired platelet activation can be result of many common pathologies or interventions. Arterial thrombosis and the acute ischemic events that follow, such as myocardial infarction and ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Novel Antithrombotic Diadenosine Tetraphosphate Analogs
Amount: $3,396,941.00DESCRIPTION Undesired platelet activation can be result of many common pathologies or interventions Arterial thrombosis and the acute ischemic events that follow such as myocardial infarction and ...
SBIRPhase II2013Department of Health and Human Services National Institutes of Health -
Oral prodrug of a novel antiviral that blocks neuronal reactivation of HSV
Amount: $300,000.00DESCRIPTION (provided by applicant): There is no cure for herpes simplex virus (HSV) latent infections of neurons, and the possibility of asymptomatic reactivation and simultaneous transfer of inf ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Analogs of GTP as novel inhibitors of bacterial c-di-GMP-synthesizing enzymes
Amount: $299,848.00DESCRIPTION (provided by applicant): The bacterial second messenger c-di-GMP (cyclo-(GMP)2) is responsible for inducing certain pathogenic bacteria to form biofilms, complex structures of one or more ...
SBIRPhase I2010Department of Health and Human Services National Institutes of Health -
Preclinical development of a novel antibacterial for Clostridium difficile diseas
Amount: $3,000,000.00ABSTRACT Among inhibitors of Gram+ DNA polymerases IIIC and IIIE, several compounds are active against multiple strains of the anaerobic Gram+ bacterium Clostridium difficile (Cdiff). The compounds a ...
SBIRPhase II2010Department of Health and Human Services National Institutes of Health
